Welcome to GlycoScientific
We are developing tools to enable research in glycobiology, an emerging field of research focused on the identification, characterization, and quantitation of sugars, saccharides, and/ or glycans. These molecules are essential components to all living things and play important functions in various biological events such as cell-cell recognition, signal transduction, tumorigenesis, and epigenetics. Alterations to these glycans are important medically since they are often associated with diseases, such as cancer, diabetes, heart disease, Alzheimer’s, and autoimmune disorders.
GlycoScientific has developed a patent-pending process to produce glycoproteins whose glycans are isotopically labeled (iGlycan). These are ideal for the qualitative and quantitative analysis of glycoprotein glycans, and can be applied to individual glycans or complex mixtures such as including that perfomed in the field of glycomics. The first product in this line of reagents is iGlycoMAb, a monoclonal antibody (mAb) that is an ideal internal standard for the analysis of glycans on native IgGs, mAbs, and fusion proteins. However, iGlycoMAb can be applied to individual glycans or complex mixtures such as those observed in the field of glycomics.
iGlycoMAb was highlighted by various presentations at the 2015 American Society for Mass Spectrometry (ASMS) conference, including an oral presentation by our founder, Dr. Ron Orlando, which can be viewed here.
Advantages of iGlycan:
- No alteration to mass spectrometry (MS) based workflows.
- Enhanced accuracy and precision.
- Comparable results from researchers in geographically different places.
- Absolute quantitation of glycans attached to glycoprotein.